Literature DB >> 20705131

Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome.

Paul Ashwood1, Paula Krakowiak, Irva Hertz-Picciotto, Robin Hansen, Isaac Pessah, Judy Van de Water.   

Abstract

Autism spectrum disorders (ASD) are characterized by impairment in social interactions, communication deficits, and restricted repetitive interests and behaviors. A potential role for immune dysfunction has been suggested in ASD. To test this hypothesis, we investigated evidence of differential cytokine release in plasma samples obtained from 2 to 5 year-old children with ASD compared with age-matched typically developing (TD) children and children with developmental disabilities other than autism (DD). Participants were recruited as part of the population based case-control CHARGE (Childhood Autism Risks from Genetics and Environment) study and included: 97 participants with a confirmed diagnosis of ASD using standard assessments (DSM IV criteria and ADOS, ADI-R), 87 confirmed TD controls, and 39 confirmed DD controls. Plasma was isolated and cytokine production was assessed by multiplex Luminex™ analysis. Observations indicate significant increases in plasma levels of a number of cytokines, including IL-1β, IL-6, IL-8 and IL-12p40 in the ASD group compared with TD controls (p<0.04). Moreover, when the ASD group was separated based on the onset of symptoms, it was noted that the increased cytokine levels were predominantly in children who had a regressive form of ASD. In addition, increasing cytokine levels were associated with more impaired communication and aberrant behaviors. In conclusion, using larger number of participants than previous studies, we report significantly shifted cytokine profiles in ASD. These findings suggest that ongoing inflammatory responses may be linked to disturbances in behavior and require confirmation in larger replication studies. The characterization of immunological parameters in ASD has important implications for diagnosis, and should be considered when designing therapeutic strategies to treat core symptoms and behavioral impairments of ASD.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20705131      PMCID: PMC2991432          DOI: 10.1016/j.bbi.2010.08.003

Source DB:  PubMed          Journal:  Brain Behav Immun        ISSN: 0889-1591            Impact factor:   7.217


  47 in total

1.  Activation of the inflammatory response system in autism.

Authors:  Jan Croonenberghs; Eugene Bosmans; Dirk Deboutte; Gunter Kenis; Michael Maes
Journal:  Neuropsychobiology       Date:  2002       Impact factor: 2.328

2.  TNFalpha contributes to the death of NGF-dependent neurons during development.

Authors:  V Barker; G Middleton; F Davey; A M Davies
Journal:  Nat Neurosci       Date:  2001-12       Impact factor: 24.884

Review 3.  Leukemia inhibitory factor, Interleukin 6, and other cytokines using the GP130 transducing receptor: roles in inflammation and injury.

Authors:  R A Gadient; P H Patterson
Journal:  Stem Cells       Date:  1999       Impact factor: 6.277

4.  Antibodies to neuron-specific antigens in children with autism: possible cross-reaction with encephalitogenic proteins from milk, Chlamydia pneumoniae and Streptococcus group A.

Authors:  A Vojdani; A W Campbell; E Anyanwu; A Kashanian; K Bock; E Vojdani
Journal:  J Neuroimmunol       Date:  2002-08       Impact factor: 3.478

5.  Autoantibody repertoires to brain tissue in autism nuclear families.

Authors:  Susana C Silva; Catarina Correia; Constantin Fesel; Marta Barreto; Ana M Coutinho; Carla Marques; Teresa S Miguel; Assunção Ataide; Celeste Bento; Luis Borges; Guiomar Oliveira; Astrid M Vicente
Journal:  J Neuroimmunol       Date:  2004-07       Impact factor: 3.478

6.  Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring.

Authors:  Limin Shi; S Hossein Fatemi; Robert W Sidwell; Paul H Patterson
Journal:  J Neurosci       Date:  2003-01-01       Impact factor: 6.167

7.  High nitric oxide production in autistic disorder: a possible role for interferon-gamma.

Authors:  Thayne L Sweeten; David J Posey; Sudha Shankar; Christopher J McDougle
Journal:  Biol Psychiatry       Date:  2004-02-15       Impact factor: 13.382

8.  Intestinal lymphocyte populations in children with regressive autism: evidence for extensive mucosal immunopathology.

Authors:  Paul Ashwood; Andrew Anthony; Alicia A Pellicer; Franco Torrente; John A Walker-Smith; Andrew J Wakefield
Journal:  J Clin Immunol       Date:  2003-11       Impact factor: 8.317

Review 9.  Interleukin-6 (IL-6): a possible neuromodulator induced by neuronal activity.

Authors:  Eric Jüttler; Victoria Tarabin; Markus Schwaninger
Journal:  Neuroscientist       Date:  2002-06       Impact factor: 7.519

10.  Neuroglial activation and neuroinflammation in the brain of patients with autism.

Authors:  Diana L Vargas; Caterina Nascimbene; Chitra Krishnan; Andrew W Zimmerman; Carlos A Pardo
Journal:  Ann Neurol       Date:  2005-01       Impact factor: 10.422

View more
  292 in total

1.  Risperidone-related improvement of irritability in children with autism is not associated with changes in serum of epidermal growth factor and interleukin-13.

Authors:  Zuzana Tobiasova; Klaas H B van der Lingen; Lawrence Scahill; James F Leckman; Yan Zhang; Wookjin Chae; James T McCracken; Christopher J McDougle; Benedetto Vitiello; Elaine Tierney; Michael G Aman; L Eugene Arnold; Liliya Katsovich; Pieter J Hoekstra; Fred Volkmar; Alfred L M Bothwell; Ivana Kawikova
Journal:  J Child Adolesc Psychopharmacol       Date:  2011-11-09       Impact factor: 2.576

2.  Increased production of IL-17 in children with autism spectrum disorders and co-morbid asthma.

Authors:  Marjannie Eloi Akintunde; Melissa Rose; Paula Krakowiak; Luke Heuer; Paul Ashwood; Robin Hansen; Irva Hertz-Picciotto; Judy Van de Water
Journal:  J Neuroimmunol       Date:  2015-07-11       Impact factor: 3.478

3.  A Prospective Evaluation of Systemic Biomarkers and Cognitive Function Associated with Carotid Revascularization.

Authors:  Mary C Zuniga; Thuy B Tran; Brittanie D Baughman; Gayatri Raghuraman; Elizabeth Hitchner; Allyson Rosen; Wei Zhou
Journal:  Ann Surg       Date:  2016-10       Impact factor: 12.969

Review 4.  Beyond the brain: A multi-system inflammatory subtype of autism spectrum disorder.

Authors:  Robyn P Thom; Christopher J Keary; Michelle L Palumbo; Caitlin T Ravichandran; Jennifer E Mullett; Eric P Hazen; Ann M Neumeyer; Christopher J McDougle
Journal:  Psychopharmacology (Berl)       Date:  2019-05-28       Impact factor: 4.530

5.  Asthma and Allergies in Children With Autism Spectrum Disorders: Results From the CHARGE Study.

Authors:  Kristen Lyall; Judy Van de Water; Paul Ashwood; Irva Hertz-Picciotto
Journal:  Autism Res       Date:  2015-02-26       Impact factor: 5.216

6.  Comorbidity clusters in autism spectrum disorders: an electronic health record time-series analysis.

Authors:  Finale Doshi-Velez; Yaorong Ge; Isaac Kohane
Journal:  Pediatrics       Date:  2013-12-09       Impact factor: 7.124

7.  Neurotensin stimulates sortilin and mTOR in human microglia inhibitable by methoxyluteolin, a potential therapeutic target for autism.

Authors:  Arti B Patel; Irene Tsilioni; Susan E Leeman; Theoharis C Theoharides
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-23       Impact factor: 11.205

8.  Cannabinoid receptor type 2, but not type 1, is up-regulated in peripheral blood mononuclear cells of children affected by autistic disorders.

Authors:  Dario Siniscalco; Anna Sapone; Catia Giordano; Alessandra Cirillo; Laura de Magistris; Francesco Rossi; Alessio Fasano; James Jeffrey Bradstreet; Sabatino Maione; Nicola Antonucci
Journal:  J Autism Dev Disord       Date:  2013-11

Review 9.  Inflammatory profiles in the BTBR mouse: how relevant are they to autism spectrum disorders?

Authors:  Milo Careaga; Jared Schwartzer; Paul Ashwood
Journal:  Brain Behav Immun       Date:  2014-06-14       Impact factor: 7.217

Review 10.  Cytokine aberrations in autism spectrum disorder: a systematic review and meta-analysis.

Authors:  A Masi; D S Quintana; N Glozier; A R Lloyd; I B Hickie; A J Guastella
Journal:  Mol Psychiatry       Date:  2014-06-17       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.